249 related articles for article (PubMed ID: 8602889)
1. [14-O-hemiesters and 13-hydrazones of anthracyline antibiotics of the daunorubicin series. Synthesis and cytostatic activity with respect to tumor cells sensitive or resistant to doxorubicin].
Povarov LS; Leont'eva OV; Bernaki PD; Olsuf'eva EN; Salimova EI; Pera P; Preobrazhenskaia MN
Bioorg Khim; 1995 Dec; 21(12):925-32. PubMed ID: 8602889
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antitumor activity of 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl) daunomycinone derivatives modified at C-3' or C-4'.
Takagi Y; Kobayashi N; Chang MS; Lim GJ; Tsuchiya T
Carbohydr Res; 1998 Feb; 307(3-4):217-32. PubMed ID: 9675364
[TBL] [Abstract][Full Text] [Related]
3. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
4. Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxorubicin and mitoxantrone.
Zijlstra JG; Meijer C; Timmer-Bosscha H; Le TK; de Vries EG; Mulder NH
Eur J Respir Dis Suppl; 1987; 149():53-5. PubMed ID: 3034649
[No Abstract] [Full Text] [Related]
5. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies on anthracycline haloderivatives.
Facchinetti T; Geroni C; Fumagalli A; Giuliani FC
Drugs Exp Clin Res; 1986; 12(8):657-61. PubMed ID: 3463498
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory activity of four demethoxy fluorinated anthracycline analogs against five human-tumor cell lines.
Horton D; Khare A
Bioorg Med Chem Lett; 2010 Nov; 20(21):6179-81. PubMed ID: 20850305
[TBL] [Abstract][Full Text] [Related]
8. Quantitative models for growth inhibition of human leukemia cells by antitumor anthracycline derivatives.
Kanter PM; Schwartz HS
Cancer Res; 1979 Sep; 39(9):3661-72. PubMed ID: 476691
[TBL] [Abstract][Full Text] [Related]
9. Oxazolinodoxorubicin - a promising new anthracycline.
Lukawska M; Klopotowska D; Milczarek M; Wietrzyk J; Studzian K; Szmigiero L; Porebska A; Oszczapowicz I
Anticancer Res; 2012 Jul; 32(7):2959-65. PubMed ID: 22753760
[TBL] [Abstract][Full Text] [Related]
10. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
11. Biological properties of new derivatives of daunorubicin.
Wasowska-Lukawska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
In Vivo; 2007; 21(2):413-6. PubMed ID: 17436596
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics.
Studzian K; Wasowska M; Piestrzeniewicz MK; Wilmańska D; Szmigiero L; Oszczapowicz I; Gniazdowski M
Neoplasma; 2001; 48(5):412-8. PubMed ID: 11845988
[TBL] [Abstract][Full Text] [Related]
13. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitivity of drug-sensitive and drug-resistant P388 leukemia cell lines after hyperthermic treatment.
Toffoli G; Bevilacqua C; Franceschin A; Boiocchi M
J Chemother; 1989 Jul; 1(4 Suppl):1159-61. PubMed ID: 16312815
[No Abstract] [Full Text] [Related]
15. Synthesis of daunorubicin analogues containing truncated aromatic cores and unnatural monosaccharide residues.
Fan E; Shi W; Lowary TL
J Org Chem; 2007 Apr; 72(8):2917-28. PubMed ID: 17373847
[TBL] [Abstract][Full Text] [Related]
16. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
Taatjes DJ; Fenick DJ; Koch TH
J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of a new bisintercalating anthracycline antibiotic.
Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
[TBL] [Abstract][Full Text] [Related]
18. Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
Fenick DJ; Taatjes DJ; Koch TH
J Med Chem; 1997 Aug; 40(16):2452-61. PubMed ID: 9258351
[TBL] [Abstract][Full Text] [Related]
19. [Derivatives of antineoplastic antibiotics of the daunorubicin series containing methylurea or nitrosomethylurea residues].
Povarov LS; Bakina EV; Lazhko EI; Orlova GI; Zhukova OS; Obidniak NA; Iurchenko GI; Glazkova TIu; Preobrazhenskaia MN
Bioorg Khim; 1990 Apr; 16(4):559-68. PubMed ID: 2375780
[TBL] [Abstract][Full Text] [Related]
20. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
